The Role of Obstructive Sleep Apnea in Pulmonary Hypertension Associated with Lung Diseases (Group 3 Pulmonary Hypertension): A Narrative Review
Issued Date
2025-08-01
Resource Type
eISSN
20770383
Scopus ID
2-s2.0-105013237097
Journal Title
Journal of Clinical Medicine
Volume
14
Issue
15
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Medicine Vol.14 No.15 (2025)
Suggested Citation
Tripipitsiriwat A., Malhotra A., Robertson H., Kim N.H., Yang J.Z., Raphelson J. The Role of Obstructive Sleep Apnea in Pulmonary Hypertension Associated with Lung Diseases (Group 3 Pulmonary Hypertension): A Narrative Review. Journal of Clinical Medicine Vol.14 No.15 (2025). doi:10.3390/jcm14155442 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/111799
Title
The Role of Obstructive Sleep Apnea in Pulmonary Hypertension Associated with Lung Diseases (Group 3 Pulmonary Hypertension): A Narrative Review
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Obstructive sleep apnea (OSA) could increase pulmonary artery pressure. However, the clinical consequences vary, mainly depending on comorbidities. Patients with pulmonary hypertension associated with lung diseases (World Health Organization (WHO) Group 3 pulmonary hypertension) are particularly vulnerable increases in pulmonary artery pressure. Managing pulmonary hypertension in this specific patient population presents a considerable challenge. While positive airway pressure therapy for OSA has shown promise in improving pulmonary hemodynamics in patients with obesity hypoventilation syndrome and chronic obstructive pulmonary disease, evidence is lacking for similar improvements in those with other pulmonary diseases and hypoventilation disorders. Furthermore, pulmonary-artery-specific therapies may carry a risk of clinical worsening in this group. Weight management and new pharmacotherapy have together emerged as a crucial intervention, demonstrating benefits for both OSA and pulmonary hemodynamics. We reviewed key studies that provide insights into the influence of OSA on WHO Group 3 pulmonary hypertension and the clinical management of both conditions.